By Michael Erman and Sriparna Roy (Reuters) -Bristol Myers Squibb on Thursday said its 2025 revenue would fall more sharply ...

Ed: As usual, a disappointing lack of ambition from the senior management to push hard for promotion. They blame the transfer ...

Bristol Myers Squibb on Thursday posted better-than-expected fourth quarter earnings, but said its 2025 revenue would fall ...

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Bristol Myers so ...

The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...

Bristol Myers Squibb Co. released sales and profit forecasts for 2025 below Wall Street’s expectations — a sign the company’s ...

(Reuters) -Bristol Myers Squibb on Thursday posted better-than-expected fourth-quarter earnings, but said its 2025 revenue ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

The waste-to-energy company has continued to operate in the state as other WTE projects shut down. With state lawmakers ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Bristol Myers Squibb stock tumbled Thursday on a light outlook for 2025 following a strong fourth-quarter report.

BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion ...